ClinicalTrials.gg
CompletedNCT00174460AGAUpdated Apr 5, 2017Results posted

Somatropin Therapy In Children Born Preterm But Appropriate For Gestational Age

A Phase 2 interventional study of Somatropin and Control Arm in Growth Hormone Therapy and Infant, Very Low Birth Weight, sponsored by Pfizer. Completed at 8 sites in Germany. Open to participants aged 4 Years to 10 Years. Per ClinicalTrials.gov, last updated 2017-04-05.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
4 Years to 10 Years
Sex
All
01

Study summary

Safety and efficacy of Somatropin will be evaluated in short children born with a list weight below 1500 g and that did not catch up to normal height at the age of 4.

02

Conditions studied

  • Growth Hormone Therapy
  • Infant, Very Low Birth Weight

Browse trials for

03

In context

Birth Weight

185 studies on the registry are indexed under Birth Weight; 24 are open to participants now.

This study's enrollment of 33 is below the median of 170 across 117 interventional studies indexed under Birth Weight.

Browse Birth Weight studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 146 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial:

  • Prepubertal caucasian boys between 4 and 10 years of age and girls between 4 and 9 years of age.
  • Girls: Tanner stage 1 breast development
  • Boys: Testis volume \<= 3ml
  • Tanner stage 1 pubic hair development (to exclude confounding effect of adrenarche on growth velocity, insulin sensitivity and body composition).
  • (In case of any signs or symptoms of gonadal puberty a GnRH-Test must decide if the subject is still pubertal.)
  • Height \<=-2 SD for chronological age (Brandt/Reinken).
  • Growth velocity SDS below 0 SD for chronological age (Brandt/Reinken based on 12+/- 3 months observation period before screening).
  • Premature born defined as \<=1500 g birth weight.
  • GH sufficiency (GH level > 7 ug/l following any routine GH stimulation test).
  • Written of both parents (legal guardians) and oral/written consent of subject due to age specific information.

Exclusion criteria

Exclusion Criteria:

Subjects presenting with any of the following will not be included in the trial:

  • Other endocrine diseases except for well substituted hypothyroidism.
  • Severe chronic diseases or medication that might influence linear growth or insulin sensitivity (e.g. ).
  • Positive GAD and IA-2 antibodies (for type 1 diabetes).
  • History of
  • Children who meet all of the following 4 criteria:
  • actual body height \< -2,5 SDS (Brandt/Reinken) and parent adjusted target height \< -1 SDS (Hermanussen and Cole, 2003)
  • length and/or body weight retardations adjusted to gestational age at birth \< -2,0 SDS (Lawrence et al., 1989, Voigt et al., 1996)
  • children with chronological age > = 4 years and
  • growth velocity \< 0 SDS during the last year before inclusion.
  • Chromosomal aberrations or syndromes.
  • Suspected non-compliance or impossibility to follow the two or three year treatment schedule, respectively (e.g. social implications).
  • Severe hemiparesis and severe CNS defects
  • Retinopathia > third degree or laser treatment as newborns.
  • Participation in any other clinical trial during active treatment phase.
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or product administration or may interfere with the interpretation of trial results and, in the judgement of the investigator, would make the subject inappropriate for entry into this trial.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Active comparator
    Treatment Arm

    Drug: Somatropin · Other: Control Arm

  • No intervention
    Control Arm

Interventions

  • Controlled, prospective, randomized, multicenter study with an untreated (control) group during the first year. The children will be randomized into treatment or untreated (control) group. After one year the control group will undergo GH-therapy, too. Children randomized to the control group will get the possibility to continue treatment for a further year. The study will end after 2 and 3 years of observation, respectively.

  • OtherControl Arm

    Controlled, prospective, randomized, multicenter study with an untreated (control) group during the first year. The children will be randomized into treatment or untreated (control) group. After one year the control group will undergo GH-therapy, too. The study will end after 2 and 3 years of observation, respectively. Children randomized to the control group will get the possibility to continue treatment for a further year.

06

What researchers measure

Primary outcomes

  1. Change in Height Standard Deviation Score (SDS) After 1 Year

    Change in Height SDS after 1 year where SDS=height minus mean (age-and sex-matched reference) divided by SD (age and sex-matched reference).

    Time frame: Baseline to 1 year (Month 12)

  2. Change in Growth Velocity Standard Deviation Score (SDS) After 1 Year

    Change in Growth Velocity (GV) SDS after 1 year where SDS=GV minus mean (age-and sex-matched reference) divided by SD (age and sex-matched reference).

    Time frame: Baseline to 1 year (Month 12)

Secondary outcomes

  1. Change From Baseline in Growth Velocity After 1 Year and After 2 Years

    Growth velocity measured as centimeters per year.

    Time frame: Baseline, Month 12, Month 24

  2. Change From Baseline in Growth Velocity SDS After 2 Years

    Change in Growth Velocity SDS after 2 years (24 months) where SDS = growth velocity minus mean (age-and sex-matched reference) divided by SD (age and sex-matched reference).

    Time frame: Baseline, Month 24

  3. Change From Baseline in Height After 1 Year and After 2 Years

    Time frame: Baseline, Month 12, Month 24

  4. Change From Baseline in Height SDS After 2 Years

    Change in Height SDS after 2 years (24 months) where SDS = height minus mean (age-and sex-matched reference) divided by SD (age and sex-matched reference).

    Time frame: Baseline, Month 24

  5. Change From Baseline in Body Composition (Skinfold Thickness) After 1 Year and After 2 Years: Triceps

    Body composition measured as skinfold thickness at tricep in millimeters (mm); measured halfway down the left upper arm with arm hanging in relaxed position at participant's side.

    Time frame: Baseline, Month 12, Month 24

  6. Change From Baseline in Body Composition (Skinfold Thickness) After 1 Year and After 2 Years: Subscapular

    Body composition measured as subscapular skinfold thickness in millimeters (mm); measured laterally just below the angle of the left scapula.

    Time frame: Baseline, Month 12, Month 24

  7. Change From Baseline in Body Composition (Skinfold Thickness) After 1 Year and After 2 Years: Suprailiac

    Body composition measured as suprailiac skinfold thickness in millimeters (mm); measured just above the iliac crest in the middle-axillary line.

    Time frame: Baseline, Month 12, Month 24

  8. Change From Baseline in Volumetric Cortical Bone Mineral Density (BMD) Using Peripheral Quantitative Computed Tomography (pQCT) After 1 Year and After 2 Years

    Volumetric Cortical BMD measured as milligrams per cubic millimeter (mg/mm3). BMD (proximal radius) SDS (number of standard deviations a participant's BMD differs from the average BMD of their age and sex). Baseline and post-baseline SDS values transformed to age and sex specific z-score (Ln(test result/M)\]/S); Ln=natural logarithm; M=age- or height-) and sex-specific mean value; S=age-(or height-) and sex-specific coefficient of variation) then change from baseline is calculated. Positive values are above the average for participant's age and sex; negative values are below the average.

    Time frame: Baseline, Month 12, Month 24

  9. Change From Baseline in Bone Structure Using pQCT After 1 Year and 2 Years: Cortical Cross-sectional Area (CSA)

    Bone structure Cortical CSA measured as millimeters squared (mm2). CSA (proximal radius) SDS (number of standard deviations a participant's CSA differs from the average CSA of their age and sex). Baseline and post-baseline SDS values transformed to age and sex specific z-score (Ln(test result/M)\]/S); Ln=natural logarithm; M=age- or height-) and sex-specific mean value; S=age-(or height-) and sex-specific coefficient of variation) then change from baseline is calculated. Positive values are above the average for participant's age and sex; negative values are below the average.

    Time frame: Baseline, Month 12, Month 24

  10. Change From Baseline in Bone Structure Using Peripheral Quantitative Computed Tomography (pQCT) After 1 Year and 2 Years: Total Cross-sectional Area (CSA)

    Bone structure Total CSA measured as millimeters squared (mm2). Total CSA (proximal radius) SDS (number of standard deviations a participant's CSA differs from the average CSA of their age and sex). Baseline and post-baseline SDS values transformed to age and sex specific z-score (Ln(test result/M)\]/S); Ln=natural logarithm; M=age- or height-) and sex-specific mean value; S=age-(or height-) and sex-specific coefficient of variation) then change from baseline is calculated. Positive values are above the average for participant's age and sex; negative values are below the average.

    Time frame: Baseline, Month 12, Month 24

  11. Change From Baseline in Bone Structure Using pQCT After 1 Year and 2 Years: Muscle Cross-sectional Area (CSA)

    Bone structure Muscle CSA measured as millimeters squared (mm2). CSA (proximal radius) SDS (number of standard deviations a participant's CSA differs from the average CSA of their age and sex). Baseline and post-baseline SDS values transformed to age and sex specific z-score (Ln(test result/M)\]/S); Ln=natural logarithm; M=age- or height-) and sex-specific mean value; S=age-(or height-) and sex-specific coefficient of variation) then change from baseline is calculated. Positive values are above the average for participant's age and sex; negative values are below the average.

    Time frame: Baseline, Month 12, Month 24

  12. Change From Baseline in Bone Structure Using pQCT After 1 Year and 2 Years: Cortical Thickness (CT)

    Cortical Thickness measured as millimeters (mm). CT (proximal radius) SDS (number of standard deviations a participant's CT differs from the average CT of their age and sex). Baseline and post-baseline SDS values transformed to age and sex specific z-score (Ln(test result/M)\]/S); Ln=natural logarithm; M=age- or height-) and sex-specific mean value; S=age-(or height-) and sex-specific coefficient of variation) then change from baseline is calculated. Positive values are above the average for participant's age and sex; negative values are below the average.

    Time frame: Baseline, Month 12, Month 24

  13. Change From Baseline in Bone Structure Using pQCT After 1 Year and 2 Years: Marrow Area (MA)

    Marrow Area measured as millimeters squared (mm2). MA (proximal radius) SDS (number of standard deviations a participant's MA differs from the average MA of their age and sex). Baseline and post-baseline SDS values transformed to age and sex specific z-score (Ln(test result/M)\]/S); Ln=natural logarithm; M=age- or height-) and sex-specific mean value; S=age-(or height-) and sex-specific coefficient of variation) then change from baseline is calculated. Positive values are above the average for participant's age and sex; negative values are below the average.

    Time frame: Baseline, Month 12, Month 24

  14. Change From Baseline in Bone Stability Using pQCT After 1 Year and After 2 Years: Strength-strain Index (SSI)

    Bone stability expressed as polar SSI in cubic millimeters (mm3). SSI (proximal radius) SDS (number of standard deviations a participant's SSI differs from the average SSI of their age and sex). Baseline and post-baseline SDS values transformed to age and sex specific z-score (Ln(test result/M)\]/S); Ln=natural logarithm; M=age- or height-) and sex-specific mean value; S=age-(or height-) and sex-specific coefficient of variation) then change from baseline is calculated. Positive values are above the average for participant's age and sex; negative values are below the average.

    Time frame: Baseline, Month 12, Month 24

  15. Change From Baseline in Muscle Strength: Hand Grip SDS After 1 Year and After 2 Years

    Muscle strength determined by measuring grip force (kilograms) using hand grip dynamometer for participants ≥6 years of age. Baseline and post-baseline SDS values transformed to age and sex specific z-score. Change in hand grip calculated as SDS where SDS = hand grip minus mean (age- and sex-matched reference) divided by SD (age- and sex-matched reference). Positive values are above the average for participant's age and sex; negative values are below the average.

    Time frame: Baseline, Month 12, Month 24

  16. Number of Participants With Change in Insulin Sensitivity: Somatropin

    Insulin sensitivity calculated as incidence of pathological glucose intolerance assessed prior to randomization (Screening Day -3 to Baseline Day 0) and at final visit (final visit: Somatropin treatment group=Month 24). Pathological glucose intolerance (oral glucose tolerance test) measured as venous (blood or plasma) with range minimum 120 milligrams per deciliter (mg/dL) to \>140 mg/dL; capillary (blood) with range minimum 120 mg/dL to \>120 mg/dL; or method not known with range minimum 120 mg/dL to \>120 mg/dL.

    Time frame: Baseline, Month 24

  17. Number of Participants With Change in Insulin Sensitivity: Control Arm

    Insulin sensitivity calculated as incidence of pathological glucose intolerance assessed prior to randomization (Screening Day -3 to Baseline Day 0) and at final visit (final visit: Control Arm=Month 36). Pathological glucose intolerance (oral glucose tolerance test) measured as venous (blood or plasma) with range minimum 120 milligrams per deciliter (mg/dL) to \>140 mg/dL; capillary (blood) with range minimum 120 mg/dL to \>120 mg/dL; or method not known with range minimum 120 mg/dL to \>120 mg/dL.

    Time frame: Baseline, Month 36

  18. Growth Curve Comparison Based on Height SDS

    Growth curve comparison with height SDS in centimeters as the dependent variable; SDS = height minus mean (age-and sex-matched reference) divided by SD (age and sex-matched reference).

    Time frame: Month 12, Month 24

  19. Growth Curve Comparison Based on Height SDS: Control Arm

    Growth curve comparison with height SDS in centimeters as the dependent variable; SDS = height minus mean (age-and sex-matched reference) divided by SD (age and sex-matched reference). Control Arm final visit=Month 36.

    Time frame: Month 36

  20. Growth Curve Comparison Based on Height

    Growth curve comparison with height in centimeters as the dependent variable.

    Time frame: Month 12, Month 24

  21. Growth Curve Comparison Based on Height: Control Arm

    Growth curve comparison with height in centimeters as the dependent variable.

    Time frame: Month 36

07

Results

Posted May 12, 2009
Limitations and caveats
Result values for the primary outcome measures were revised at the final analysis due to programmatic corrections: age rounded up if \>6 months past last birthday. Height and height SDS not rounded for final analysis; rounded only for the reports.

Participant flow

Participant flow — Overall Study
MilestoneSomatropinControl Arm
Started1815
Received study treatment1814
Completed1814
Not completed01
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryChange in Height Standard Deviation Score (SDS) After 1 Year

Change in Height SDS after 1 year where SDS=height minus mean (age-and sex-matched reference) divided by SD (age and sex-matched reference).

Time frame:
Baseline to 1 year (Month 12)
Reported as:
Least squares mean · centimeters
Change in Height Standard Deviation Score (SDS) After 1 Year
centimetersSomatropinControl Arm
Change in Height Standard Deviation Score (SDS) After 1 Year1.099 ± 0.07140.108 ± 0.0783
Statistical analysis
  • Somatropin vs Control Arm · ANCOVA · p = <0.001 · Mean difference (final values): 0.991 · 95% CI 0.773 to 1.210Results from analysis of covariance method (ANCOVA) adjusted for baseline height SDS and target height SDS; Last observation carried forward (LOCF).
SecondaryChange From Baseline in Growth Velocity After 1 Year and After 2 Years

Growth velocity measured as centimeters per year.

Time frame:
Baseline, Month 12, Month 24
Reported as:
Least squares mean · centimeters per year
Change From Baseline in Growth Velocity After 1 Year and After 2 Years
centimeters per yearSomatropinControl Arm
Month 125.110 ± 0.26230.695 ± 0.2881
Month 243.049 ± 0.35463.934 ± 0.3893
Statistical analysis
  • Somatropin vs Control Arm · ANCOVA · p = <0.001 · Mean difference (final values): 4.415 · 95% CI 3.605 to 5.225Results from ANCOVA adjusted for baseline growth velocity, target height SDS, sex, and age; LOCF.
  • Somatropin vs Control Arm · ANCOVA · p = 0.108 · Mean difference (final values): -0.884 · 95% CI -1.977 to 0.208Results from ANCOVA adjusted for baseline growth velocity, target height SDS, sex, and age; LOCF.
SecondaryChange From Baseline in Growth Velocity SDS After 2 Years

Change in Growth Velocity SDS after 2 years (24 months) where SDS = growth velocity minus mean (age-and sex-matched reference) divided by SD (age and sex-matched reference).

Time frame:
Baseline, Month 24
Reported as:
Least squares mean · centimeters per year
Change From Baseline in Growth Velocity SDS After 2 Years
centimeters per yearSomatropinControl Arm
Change From Baseline in Growth Velocity SDS After 2 Years4.751 ± 0.47165.825 ± 0.5177
Statistical analysis
  • Somatropin vs Control Arm · ANCOVA · p = 0.141 · Mean difference (final values): -1.074 · 95% CI -2.524 to 0.376Results from ANCOVA adjusted for baseline growth velocity SDS and target height SDS; LOCF.
SecondaryChange From Baseline in Height After 1 Year and After 2 Years
Time frame:
Baseline, Month 12, Month 24
Reported as:
Least squares mean · centimeters
Change From Baseline in Height After 1 Year and After 2 Years
centimetersSomatropinControl Arm
Month 1210.467 ± 0.24395.927 ± 0.2677
Month 2418.908 ± 0.650714.844 ± 0.7149
Statistical analysis
  • Somatropin vs Control Arm · ANCOVA · p = <0.001 · Mean difference (final values): 4.540 · 95% CI 3.789 to 5.291Results from ANCOVA adjusted for baseline height, target height SDS, sex, and age; LOCF.
  • Somatropin vs Control Arm · ANCOVA · p = <0.001 · Mean difference (final values): 4.064 · 95% CI 2.049 to 6.080Results from ANCOVA adjusted for baseline height, target height SDS, sex, and age; LOCF.
SecondaryChange From Baseline in Height SDS After 2 Years

Change in Height SDS after 2 years (24 months) where SDS = height minus mean (age-and sex-matched reference) divided by SD (age and sex-matched reference).

Time frame:
Baseline, Month 24
Reported as:
Least squares mean · centimeters
Change From Baseline in Height SDS After 2 Years
centimetersSomatropinControl Arm
Change From Baseline in Height SDS After 2 Years1.710 ± 0.10750.991 ± 0.1179
Statistical analysis
  • Somatropin vs Control Arm · ANCOVA · p = <0.001 · Mean difference (final values): 0.719 · 95% CI 0.390 to 1.047Results from ANCOVA adjusted for baseline height SDS and target height SDS; LOCF.
SecondaryChange From Baseline in Body Composition (Skinfold Thickness) After 1 Year and After 2 Years: Triceps

Body composition measured as skinfold thickness at tricep in millimeters (mm); measured halfway down the left upper arm with arm hanging in relaxed position at participant's side.

Time frame:
Baseline, Month 12, Month 24
Reported as:
Least squares mean · millimeters
Change From Baseline in Body Composition (Skinfold Thickness) After 1 Year and After 2 Years: Triceps
millimetersSomatropinControl Arm
Month 12-2.20 ± 0.3410.50 ± 0.353
Month 24-1.30 ± 0.511-0.83 ± 0.548
Statistical analysis
  • Somatropin vs Control Arm · ANCOVA · p = <0.001 · Mean difference (final values): -2.70 · 95% CI -3.73 to -1.68Results from ANCOVA adjusted for baseline skinfold thickness, target height SDS, age, and sex; LOCF.
  • Somatropin vs Control Arm · ANCOVA · p = 0.537 · Mean difference (final values): -0.48 · 95% CI -2.04 to 1.09Results from ANCOVA adjusted for baseline skinfold thickness, target height SDS, age, and sex; LOCF.
SecondaryChange From Baseline in Body Composition (Skinfold Thickness) After 1 Year and After 2 Years: Subscapular

Body composition measured as subscapular skinfold thickness in millimeters (mm); measured laterally just below the angle of the left scapula.

Time frame:
Baseline, Month 12, Month 24
Reported as:
Least squares mean · millimeters
Change From Baseline in Body Composition (Skinfold Thickness) After 1 Year and After 2 Years: Subscapular
millimetersSomatropinControl Arm
Month 120.08 ± 0.2760.46 ± 0.286
Month 240.27 ± 0.2310.50 ± 0.247
Statistical analysis
  • Somatropin vs Control Arm · ANCOVA · p = 0.364 · Mean difference (final values): -0.37 · 95% CI -1.21 to 0.46Results from ANCOVA adjusted for baseline skinfold thickness, target height SDS, sex, and age; LOCF.
  • Somatropin vs Control Arm · ANCOVA · p = 0.506 · Mean difference (final values): -0.23 · 95% CI -0.94 to 0.48Results from ANCOVA adjusted for baseline skinfold thickness, target height SDS, sex, and age; LOCF.
SecondaryChange From Baseline in Body Composition (Skinfold Thickness) After 1 Year and After 2 Years: Suprailiac

Body composition measured as suprailiac skinfold thickness in millimeters (mm); measured just above the iliac crest in the middle-axillary line.

Time frame:
Baseline, Month 12, Month 24
Reported as:
Least squares mean · millimeters
Change From Baseline in Body Composition (Skinfold Thickness) After 1 Year and After 2 Years: Suprailiac
millimetersSomatropinControl Arm
Month 120.51 ± 0.7830.45 ± 0.849
Month 240.90 ± 0.6880.79 ± 0.774
Statistical analysis
  • Somatropin vs Control Arm · ANCOVA · p = 0.959 · Mean difference (final values): 0.06 · 95% CI -2.42 to 2.54Results from ANCOVA adjusted for baseline skinfold thickness, target height SDS, sex, and age; LOCF.
  • Somatropin vs Control Arm · ANCOVA · p = 0.919 · Mean difference (final values): 0.11 · 95% CI -2.11 to 2.32Results from ANCOVA adjusted for baseline skinfold thickness, target height SDS, sex, and age; LOCF.
SecondaryChange From Baseline in Volumetric Cortical Bone Mineral Density (BMD) Using Peripheral Quantitative Computed Tomography (pQCT) After 1 Year and After 2 Years

Volumetric Cortical BMD measured as milligrams per cubic millimeter (mg/mm3). BMD (proximal radius) SDS (number of standard deviations a participant's BMD differs from the average BMD of their age and sex). Baseline and post-baseline SDS values transformed to age and sex specific z-score (Ln(test result/M)\]/S); Ln=natural logarithm; M=age- or height-) and sex-specific mean value; S=age-(or height-) and sex-specific coefficient of variation) then change from baseline is calculated. Positive values are above the average for participant's age and sex; negative values are below the average.

Time frame:
Baseline, Month 12, Month 24
Reported as:
Least squares mean · z-score
Change From Baseline in Volumetric Cortical Bone Mineral Density (BMD) Using Peripheral Quantitative Computed Tomography (pQCT) After 1 Year and After 2 Years
z-scoreSomatropinControl Arm
Month 12 (n=2, 6)-1.055 ± 0.6802-0.162 ± 0.3600
Month 24 (n=2, 6)0.284 ± 0.5023-0.433 ± 0.2658
Statistical analysis
  • Somatropin vs Control Arm · ANCOVA · p = 0.336 · Mean difference (final values): -0.892 · 95% CI -3.158 to 1.374Results from ANCOVA adjusted for baseline volumetric cortical bone mineral density SDS and target height SDS; LOCF.
  • Somatropin vs Control Arm · ANCOVA · p = 0.300 · Mean difference (final values): 0.717 · 95% CI -0.956 to 2.391Results from ANCOVA adjusted for baseline volumetric cortical bone mineral density SDS and target height SDS; LOCF.
PrimaryChange in Growth Velocity Standard Deviation Score (SDS) After 1 Year

Change in Growth Velocity (GV) SDS after 1 year where SDS=GV minus mean (age-and sex-matched reference) divided by SD (age and sex-matched reference).

Time frame:
Baseline to 1 year (Month 12)
Reported as:
Least squares mean · centimeters per year
Change in Growth Velocity Standard Deviation Score (SDS) After 1 Year
centimeters per yearSomatropinControl Arm
Change in Growth Velocity Standard Deviation Score (SDS) After 1 Year7.117 ± 0.43841.502 ± 0.4814
Statistical analysis
  • Somatropin vs Control Arm · ANCOVA · p = <0.001 · Mean difference (final values): 5.615 · 95% CI 4.266 to 6.963Results from ANCOVA adjusted for baseline growth velocity SDS and target height SDS; LOCF.
SecondaryChange From Baseline in Bone Structure Using pQCT After 1 Year and 2 Years: Cortical Cross-sectional Area (CSA)

Bone structure Cortical CSA measured as millimeters squared (mm2). CSA (proximal radius) SDS (number of standard deviations a participant's CSA differs from the average CSA of their age and sex). Baseline and post-baseline SDS values transformed to age and sex specific z-score (Ln(test result/M)\]/S); Ln=natural logarithm; M=age- or height-) and sex-specific mean value; S=age-(or height-) and sex-specific coefficient of variation) then change from baseline is calculated. Positive values are above the average for participant's age and sex; negative values are below the average.

Time frame:
Baseline, Month 12, Month 24
Reported as:
Least squares mean · z-score
Change From Baseline in Bone Structure Using pQCT After 1 Year and 2 Years: Cortical Cross-sectional Area (CSA)
z-scoreSomatropinControl Arm
Month 12 (n=2, 5)-0.465 ± 0.77990.017 ± 0.4559
Month 24 (n=2, 6)-0.595 ± 0.74620.609 ± 0.3907
Statistical analysis
  • Somatropin vs Control Arm · ANCOVA · p = 0.653 · Mean difference (final values): -0.482 · 95% CI -3.558 to 2.595Results from ANCOVA adjusted for baseline cortical cross-sectional area SDS and target height SDS; LOCF.
  • Somatropin vs Control Arm · ANCOVA · p = 0.251 · Mean difference (final values): -1.205 · 95% CI -3.701 to 1.292Results from ANCOVA adjusted for baseline cortical cross-sectional area SDS and target height SDS; LOCF.
SecondaryChange From Baseline in Bone Structure Using Peripheral Quantitative Computed Tomography (pQCT) After 1 Year and 2 Years: Total Cross-sectional Area (CSA)

Bone structure Total CSA measured as millimeters squared (mm2). Total CSA (proximal radius) SDS (number of standard deviations a participant's CSA differs from the average CSA of their age and sex). Baseline and post-baseline SDS values transformed to age and sex specific z-score (Ln(test result/M)\]/S); Ln=natural logarithm; M=age- or height-) and sex-specific mean value; S=age-(or height-) and sex-specific coefficient of variation) then change from baseline is calculated. Positive values are above the average for participant's age and sex; negative values are below the average.

Time frame:
Baseline, Month 12, Month 24
Reported as:
Least squares mean · z-score
Change From Baseline in Bone Structure Using Peripheral Quantitative Computed Tomography (pQCT) After 1 Year and 2 Years: Total Cross-sectional Area (CSA)
z-scoreSomatropinControl Arm
Month 12 (n=2, 5)0.375 ± 0.93450.239 ± 0.5537
Month 24 (n=2, 6)0.243 ± 0.3694-0.049 ± 0.1955
Statistical analysis
  • Somatropin vs Control Arm · ANCOVA · p = 0.914 · Mean difference (final values): 0.135 · 95% CI -3.524 to 3.795Results from ANCOVA adjusted for baseline total cross-sectional area SDS and target height SDS; LOCF.
  • Somatropin vs Control Arm · ANCOVA · p = 0.547 · Mean difference (final values): 0.292 · 95% CI -0.939 to 1.522Results from ANCOVA adjusted for baseline total cross-sectional area SDS and target height SDS; LOCF.
SecondaryChange From Baseline in Bone Structure Using pQCT After 1 Year and 2 Years: Muscle Cross-sectional Area (CSA)

Bone structure Muscle CSA measured as millimeters squared (mm2). CSA (proximal radius) SDS (number of standard deviations a participant's CSA differs from the average CSA of their age and sex). Baseline and post-baseline SDS values transformed to age and sex specific z-score (Ln(test result/M)\]/S); Ln=natural logarithm; M=age- or height-) and sex-specific mean value; S=age-(or height-) and sex-specific coefficient of variation) then change from baseline is calculated. Positive values are above the average for participant's age and sex; negative values are below the average.

Time frame:
Baseline, Month 12, Month 24
Reported as:
Least squares mean · z-score
Change From Baseline in Bone Structure Using pQCT After 1 Year and 2 Years: Muscle Cross-sectional Area (CSA)
z-scoreSomatropinControl Arm
Month 12 (n=2, 6)2.084 ± 0.3628-0.227 ± 0.1688
Month 24 (n=2, 6)2.402 ± 0.52210.776 ± 0.2428
Statistical analysis
  • Somatropin vs Control Arm · ANCOVA · p = 0.007 · Mean difference (final values): 2.310 · 95% CI 1.049 to 3.572Results from ANCOVA adjusted for baseline muscle cross-sectional area SDS and target height SDS; LOCF.
  • Somatropin vs Control Arm · ANCOVA · p = 0.068 · Mean difference (final values): 1.626 · 95% CI -0.189 to 3.440Results from ANCOVA adjusted for baseline muscle cross-sectional area SDS and target height SDS; LOCF.
SecondaryChange From Baseline in Bone Structure Using pQCT After 1 Year and 2 Years: Cortical Thickness (CT)

Cortical Thickness measured as millimeters (mm). CT (proximal radius) SDS (number of standard deviations a participant's CT differs from the average CT of their age and sex). Baseline and post-baseline SDS values transformed to age and sex specific z-score (Ln(test result/M)\]/S); Ln=natural logarithm; M=age- or height-) and sex-specific mean value; S=age-(or height-) and sex-specific coefficient of variation) then change from baseline is calculated. Positive values are above the average for participant's age and sex; negative values are below the average.

Time frame:
Baseline, Month 12, Month 24

No measurements were reported for this outcome.

SecondaryChange From Baseline in Bone Structure Using pQCT After 1 Year and 2 Years: Marrow Area (MA)

Marrow Area measured as millimeters squared (mm2). MA (proximal radius) SDS (number of standard deviations a participant's MA differs from the average MA of their age and sex). Baseline and post-baseline SDS values transformed to age and sex specific z-score (Ln(test result/M)\]/S); Ln=natural logarithm; M=age- or height-) and sex-specific mean value; S=age-(or height-) and sex-specific coefficient of variation) then change from baseline is calculated. Positive values are above the average for participant's age and sex; negative values are below the average.

Time frame:
Baseline, Month 12, Month 24

No measurements were reported for this outcome.

SecondaryChange From Baseline in Bone Stability Using pQCT After 1 Year and After 2 Years: Strength-strain Index (SSI)

Bone stability expressed as polar SSI in cubic millimeters (mm3). SSI (proximal radius) SDS (number of standard deviations a participant's SSI differs from the average SSI of their age and sex). Baseline and post-baseline SDS values transformed to age and sex specific z-score (Ln(test result/M)\]/S); Ln=natural logarithm; M=age- or height-) and sex-specific mean value; S=age-(or height-) and sex-specific coefficient of variation) then change from baseline is calculated. Positive values are above the average for participant's age and sex; negative values are below the average.

Time frame:
Baseline, Month 12, Month 24
Reported as:
Least squares mean · z-score
Change From Baseline in Bone Stability Using pQCT After 1 Year and After 2 Years: Strength-strain Index (SSI)
z-scoreSomatropinControl Arm
Month 12 (n=2, 6)0.648 ± 0.42240.088 ± 0.2243
Month 24 (n=2, 6)0.477 ± 0.39250.363 ± 0.2084
Statistical analysis
  • Somatropin vs Control Arm · ANCOVA · p = 0.331 · Mean difference (final values): 0.560 · 95% CI -0.846 to 1.965Results from ANCOVA adjusted for baseline strength-strain index SDS and target height SDS; LOCF.
  • Somatropin vs Control Arm · ANCOVA · p = 0.820 · Mean difference (final values): 0.114 · 95% CI -1.192 to 1.420Results from ANCOVA adjusted for baseline strength-strain index SDS and target height SDS; LOCF.
SecondaryChange From Baseline in Muscle Strength: Hand Grip SDS After 1 Year and After 2 Years

Muscle strength determined by measuring grip force (kilograms) using hand grip dynamometer for participants ≥6 years of age. Baseline and post-baseline SDS values transformed to age and sex specific z-score. Change in hand grip calculated as SDS where SDS = hand grip minus mean (age- and sex-matched reference) divided by SD (age- and sex-matched reference). Positive values are above the average for participant's age and sex; negative values are below the average.

Time frame:
Baseline, Month 12, Month 24
Reported as:
Least squares mean · z-score
Change From Baseline in Muscle Strength: Hand Grip SDS After 1 Year and After 2 Years
z-scoreSomatropinControl Arm
Month 12 (n=7, 5)0.37 ± 0.2680.28 ± 0.318
Month 24 (n=7, 6)1.14 ± 0.2180.92 ± 0.236
Statistical analysis
  • Somatropin vs Control Arm · ANCOVA · p = 0.844 · Mean difference (final values): 0.09 · 95% CI -0.88 to 1.05Results from ANCOVA adjusted for baseline hand grip strength SDS and target height SDS; LOCF.
  • Somatropin vs Control Arm · ANCOVA · p = 0.519 · Mean difference (final values): 0.22 · 95% CI -0.52 to 0.96Results from ANCOVA adjusted for baseline hand grip strength SDS and target height SDS; LOCF.
SecondaryNumber of Participants With Change in Insulin Sensitivity: Somatropin

Insulin sensitivity calculated as incidence of pathological glucose intolerance assessed prior to randomization (Screening Day -3 to Baseline Day 0) and at final visit (final visit: Somatropin treatment group=Month 24). Pathological glucose intolerance (oral glucose tolerance test) measured as venous (blood or plasma) with range minimum 120 milligrams per deciliter (mg/dL) to \>140 mg/dL; capillary (blood) with range minimum 120 mg/dL to \>120 mg/dL; or method not known with range minimum 120 mg/dL to \>120 mg/dL.

Time frame:
Baseline, Month 24
Reported as:
Number · participants
Number of Participants With Change in Insulin Sensitivity: Somatropin
participantsSomatropin
Baseline: tolerant18
Baseline: intolerant0
Month 24: tolerant16
Month 24: intolerant0
SecondaryNumber of Participants With Change in Insulin Sensitivity: Control Arm

Insulin sensitivity calculated as incidence of pathological glucose intolerance assessed prior to randomization (Screening Day -3 to Baseline Day 0) and at final visit (final visit: Control Arm=Month 36). Pathological glucose intolerance (oral glucose tolerance test) measured as venous (blood or plasma) with range minimum 120 milligrams per deciliter (mg/dL) to \>140 mg/dL; capillary (blood) with range minimum 120 mg/dL to \>120 mg/dL; or method not known with range minimum 120 mg/dL to \>120 mg/dL.

Time frame:
Baseline, Month 36
Reported as:
Number · participants
Number of Participants With Change in Insulin Sensitivity: Control Arm
participantsControl Arm
Baseline: tolerant14
Baseline: intolerant1
Month 36: tolerant11
Month 36: intolerant2
SecondaryGrowth Curve Comparison Based on Height SDS

Growth curve comparison with height SDS in centimeters as the dependent variable; SDS = height minus mean (age-and sex-matched reference) divided by SD (age and sex-matched reference).

Time frame:
Month 12, Month 24
Reported as:
Least squares mean · centimeters
Growth Curve Comparison Based on Height SDS
centimetersSomatropinControl Arm
Month 12-2.260 ± 0.0735-3.259 ± 0.0802
Month 24-1.638 ± 0.1016-2.327 ± 0.1122
Statistical analysis
  • Somatropin vs Control Arm · Mixed models analysis · p = <0.001 · Mean difference (final values): 0.998 · 95% CI 0.778 to 1.219Results from repeated measures mixed models analysis adjusted for baseline height SDS, visit, visit\*treatment and target height SDS.
  • Somatropin vs Control Arm · Mixed models analysis · p = <0.001 · Mean difference (final values): 0.688 · 95% CI 0.382 to 0.994Results from repeated measures mixed models analysis adjusted for baseline height SDS, visit, visit\*treatment and target height SDS.
SecondaryGrowth Curve Comparison Based on Height SDS: Control Arm

Growth curve comparison with height SDS in centimeters as the dependent variable; SDS = height minus mean (age-and sex-matched reference) divided by SD (age and sex-matched reference). Control Arm final visit=Month 36.

Time frame:
Month 36
Reported as:
Least squares mean · centimeters
Growth Curve Comparison Based on Height SDS: Control Arm
centimetersControl Arm
Growth Curve Comparison Based on Height SDS: Control Arm-1.794 ± 0.1318
SecondaryGrowth Curve Comparison Based on Height

Growth curve comparison with height in centimeters as the dependent variable.

Time frame:
Month 12, Month 24
Reported as:
Least squares mean · centimeters
Growth Curve Comparison Based on Height
centimetersSomatropinControl Arm
Month 12114.228 ± 0.3330109.644 ± 0.3733
Month 24123.351 ± 0.4830119.788 ± 0.5255
Statistical analysis
  • Somatropin vs Control Arm · Mixed models analysis · p = <0.001 · Mean difference (final values): 4.585 · 95% CI 3.806 to 5.363Results from repeated measure mixed models analysis adjusted for baseline height, sex, age, visit, visit\*treatment and target height SDS.
  • Somatropin vs Control Arm · Mixed models analysis · p = <0.001 · Mean difference (final values): 3.563 · 95% CI 2.134 to 4.992Results from repeated measure mixed models analysis adjusted for baseline height, sex, age, visit, visit\*treatment and target height SDS.
SecondaryGrowth Curve Comparison Based on Height: Control Arm

Growth curve comparison with height in centimeters as the dependent variable.

Time frame:
Month 36
Reported as:
Least squares mean · centimeters
Growth Curve Comparison Based on Height: Control Arm
centimetersControl Arm
Growth Curve Comparison Based on Height: Control Arm128.049 ± 0.7821

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Somatropin—5/18 (27.8%)13/18 (72.2%)
Control Arm—1/15 (6.7%)11/15 (73.3%)
Most frequent serious events
Most frequent serious events
EventSomatropinControl Arm
TonsillitisInfections and infestations2/180/15
Facial palsyNervous system disorders0/181/15
PyrexiaGeneral disorders1/180/15
Acute tonsillitisInfections and infestations1/180/15
Bronchitis viralInfections and infestations1/180/15
BronchopneumoniaInfections and infestations1/180/15
Ear infectionInfections and infestations1/180/15
Febrile convulsionNervous system disorders1/180/15
AsthmaRespiratory, thoracic and mediastinal disorders1/180/15
Most frequent other events
Showing 10 of 35
Most frequent other events
EventSomatropinControl Arm
TonsillitisInfections and infestations4/181/15
Acute tonsillitisInfections and infestations1/182/15
BronchitisInfections and infestations1/182/15
NasopharyngitisInfections and infestations2/182/15
RhinitisInfections and infestations2/182/15
Upper respiratory tract infectionInfections and infestations2/182/15
Febrile infectionInfections and infestations2/180/15
Attention deficit / hyperactivity disorderPsychiatric disorders2/180/15
Autoimmune thyroiditisEndocrine disorders0/181/15
HypothyroidismEndocrine disorders1/181/15

Baseline characteristics

Age, Continuous
Age, Continuous(years)SomatropinControl ArmTotal
Mean5.4 ± 1.65.7 ± 1.95.5 ± 1.7
Age, Customized
Age, Customized(Participants)SomatropinControl ArmTotal
<4 years1 ± 1.51 ± 1.92 ± 1.7
≥4 years and <8 years141125
≥8 years and <12 years336
Sex: Female, Male
Sex: Female, Male(Participants)SomatropinControl ArmTotal
Female9716
Male9817
08

Study locations

8 sites
  • Pfizer Investigational Site
    Chemnitz, 09009, Germany
  • Pfizer Investigational Site
    Erlangen, 91054, Germany
  • Pfizer Investigational Site
    Freiburg, 79106, Germany
  • Pfizer Investigational Site
    Heidelberg, 69120, Germany
  • Pfizer Investigational Site
    Homburg, 66424, Germany
  • Pfizer Investigational Site
    Koeln, 50937, Germany
  • Pfizer Investigational Site
    Leipzig, 04103, Germany
  • Pfizer Investigational Site
    Tuebingen, 72076, Germany
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2005, a primary completion of Mar 2008 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

Results were first posted in May 2009, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 15, 2005
Start
Aug 2005
Primary completionActual
Mar 2008
CompletionActual
Mar 2010
Results first posted
May 12, 2009
Last update
Apr 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00174460
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 15, 2005
Start date
Aug 2005
Primary completion
Mar 2008
Completion
Mar 2010
Results posted
May 12, 2009
Last update
Apr 5, 2017

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion